Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cytosed Inc. operates a patent portfolio within the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action in the portfolio. This action is being handled by 1 distinct examiner within 1 distinct art unit. LY, KRISTINA ELISABETH is the busiest examiner for the portfolio, currently managing 1 busiest examiner pending action.
With only 1 pending office action, the prosecution workload is highly concentrated. Practitioners should tailor their approach to the specific tendencies of LY, KRISTINA ELISABETH, as this examiner oversees the entire pending pipeline. The focus within 1 distinct art unit suggests that the subject matter is specialized within the Biotechnology & Pharmaceuticals field. Resolving the 1 busiest examiner pending action will require a clear understanding of the examiner's previous actions and the technical standards of the assigned art unit. The alignment of the 1 pending office action with a single examiner in the Biotechnology & Pharmaceuticals sector indicates a streamlined path for this specific application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LY, KRISTINA ELISABETH | 1 | 37.5% | +100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18241668 | ANTIBODY-LINKED IMMUNO-SEDIMENTATION AGENT AND METHOD OF ISOLATING A TARGET FROM A SAMPLE USING SAME | LY, KRISTINA ELISABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18241668 | ANTIBODY-LINKED IMMUNO-SEDIMENTATION AGENT AND METHOD OF ISOLATING A TARGET FROM A SAMPLE USING SAME | LY, KRISTINA ELISABETH | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18241668 | ANTIBODY-LINKED IMMUNO-SEDIMENTATION AGENT AND METHOD OF ISOLATING A TARGET FROM A SAMPLE USING SAME | LY, KRISTINA ELISABETH | 1671 | §103§112 | Non-Final OA | — | Pending | Sep 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCytosed Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Kristina Elisabeth Ly has the most, with 1 of Cytosed Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.